Industrial and Intellectual Property

  • When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy [2018]

    Category:
    Artículos
    Authors:
    Ildiko Lingvay , Elías Delgado Álvarez , Angelo Avogaro
    Date:
    01 of January of 2018
    It Is a Part of:
    Diabetes/Metabolism Research and Reviews, 34